La cadena de opciones muestra datos clave de las opciones de acciones de GRAYSCALE ETHRM CLSSIC TR by Grayscale Ethereum Classic Trust (ETC) a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para GRAYSCALE ETHRM CLSSIC TR by Grayscale Ethereum Classic Trust (ETC)..

GRAYSCALE ETHRM CLSSIC TR by Grayscale Ethereum Classic Trust (ETC) (OTC:ETCG) Bolsa, Cadena de Opciones

GRAYSCALE ETHRM CLSSIC TR by Grayscale Ethereum Classic Trust (ETC)

B of A Securities analyst Tazeen Ahmad maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and raises the price target from $13 to $15.

News

Price Target

Analyst Ratings

BCRX

B of A Securities Maintains Buy on BioCryst Pharma, Raises Price Target to $15

The Department of Justice, more than 320 individuals have been charged, uncovering nearly $15 billion in fraudulent claims, marking a significant milestone in the fight against healthcare fraud.
What Happened: The Justice Department announced the charges on Monday, revealing a staggering&nbsp;$14.6 billion in fraudulent claims. The operation, named &#8220;Operation Gold Rush,&#8221; also resulted in the seizure of assets worth over $245 million, including cash, luxury vehicles, and cryptocurrency.
The crackdown uncovered perpetrators operating from Russia, Eastern Europe, Pakistan, and several other countries. &nbsp;&#8220;These&nbsp;criminals didn't just steal someone&nbsp;else's money. They stole from&nbsp;you,&#8221; stated&nbsp;Matthew Galeotti, head of the Justice Department's criminal division. Approximately 100 licensed medical professionals, including 25 doctors, have been charged. The government has reported actual losses totaling $2.9 billion. Among the cases is a $10 billion urinary catheter scheme, underscoring the growing sophistication of transnational criminal organizations.
The scheme used stolen identities and personal information of over one million Americans, according to the Justice Department. 
The fraud, surpassing the previous record in the Justice Department's annual health care fraud crackdown, involves nearly 190 federal cases and more than 90 state cases that have been charged or unsealed since June 9.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/macro-economic-events/25/07/46188192/trump-administration-reportedly-scales-back-ambitions-for-comprehensive-trade-deals" target="_blank" rel="noreferrer noopener">Trump Administration Reportedly Scales Back Ambitions For Comprehensive Trade Deals Before Tariff Deadline</a>
Why It Matters: This crackdown on health care fraud comes months after a <a href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses">civil fraud investigation</a> into UnitedHealth Group Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Medicare billing practices by the Justice Department. The probe, which began in recent months, is set to examine UnitedHealth&#8217;s Medicare Advantage plans and physician groups following reports that the company received billions in federal payments for questionable diagnoses.
Moreover, this development is in line with the efforts to combat Medicare fraud, as outlined in Rep.&nbsp;Ro Khanna&#8216;s (D-Calif.) &#8220;Progressive Deficit Reduction Plan.&#8221; The plan, which was&nbsp;backed by billionaire investor <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45900891/mark-cuban-backs-ro-khannas-12-trillion-progressive-deficit-reduction-plan-targeting-medicare-fraud-and-military-spending">Mark Cuban</a>, aims to slash the U.S. deficit by $12 trillion over the next decade, with a significant portion of the spending cuts targeted at Medicare fraud.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/news/health-care/25/06/46056665/unitedhealth-cvs-among-major-insurers-to-fast-track-prior-authorizations-will-it-cut-profits-even-more">UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

DOJ Dismantles $14 Billion Healthcare Fraud Scheme In Largest-Ever Crackdown, Impacting Over 1 Million Americans

MSC Industrial Direct Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) shares rose on Tuesday after the company posted better-than-expected financial results for its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46190116/msc-industrial-supply-co-reports-fiscal-2025-third-quarter-results" rel="noreferrer noopener">fiscal third quarter of 2025</a>.
Net sales slipped 0.8% year over year to $971.1 million but edged past the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of $970.23 million</a>.
The company reported adjusted earnings per share of $1.08, down 18.8% year over year, topping analysts&#8217; expectations of $1.03.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46133786/top-wall-street-forecasters-revamp-msc-industrial-direct-expectations-ahead-of-q3-earnings" rel="noreferrer noopener">Top Wall Street Forecasters Revamp MSC Industrial Direct Expectations Ahead Of Q3 Earnings</a>
Average daily sales also declined 0.8% primarily due to lower volumes and a roughly 10 basis points (bps) headwind from foreign exchange rates. These negative impacts were partially offset by an approximately 80 bps contribution from pricing and about 60 bps from acquisitions.
The company reported gross margin of 41.0%, up slightly from 40.9% a year ago primarily driven by favorable price/cost relationship.
Adjusted operating income fell 21.8% to $87.2 million, while the adjusted operating margin dropped to 9% from 11.4% in the same quarter last year.
As of May 31, MSC held $71.7 million in cash and equivalents. Operating cash flow for the first nine months of fiscal 2025 totaled $253.5 million, while free cash flow reached $182 million, 129% of net income.
The company repurchased about 117,000 shares during the quarter and has returned roughly <a target="_blank" href="https://filecache.investorroom.com/ir1_mscdirect/740/FY25_Q3_Earnings_Presentation.pdf" rel="noreferrer noopener">$181 million</a> to shareholders through dividends and buybacks since the beginning of the year.
Regarding the navigation of tariff impacts, MSC Industrial has a detailed breakdown of its Cost of Goods Sold (COGS) by country of origin. Over 50% of its COGS originates from U.S., providing a strong domestic base.
Europe and China each account for approximately 10% of COGS, while the rest of the world contributes less than 25%. Canada and Mexico each represent less than 3% of COGS.
This diversified sourcing strategy, with a significant portion from U.S., helps in mitigating potential tariff exposures.
&#8220;The fiscal third quarter included encouraging data points, such as core customer sequential improvement, continued momentum in our high-touch solutions and a building productivity pipeline. Looking longer term, we remain steadfast in our commitment to restoring performance consistent with our long-term objectives of growing to 400 basis points or more above the IP Index and expanding operating margins to the mid-teens,&#8221; commented Erik Gershwind, Chief Executive Officer.
MSC expects fourth-quarter average daily sales to range from a decline of 0.5% to a gain of 1.5%, with an adjusted operating margin of 8.5% to 9%.
For fiscal year 2025, the company expects a free cash flow conversion of ~120% and capital expenditures of ~$100 million-$110 million.
Price Action: MSM shares are trading higher by 3.49% at $87.99 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46190114/boeing-spirit-deal-under-scrutiny-of-british-competition-authorities-as-initial-probe-begins-report" target="_blank" rel="noreferrer noopener">UK Antitrust Probe Targets Boeing&#8217;s Spirit Deal As Airbus Sells Off Assets</a></li>
</ul>
Photo by Karolis Kavolelis via Shutterstock

Earnings

Guidance

Movers

MSC Industrial Has An Edge With Tariffs, Can Protect Margins

BigBear.ai Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares are trading volatile Tuesday. Here&#8217;s a look at <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46172406/bigbear-ai-bbai-stock-is-up-20-whats-going-on">what&#8217;s going on</a>.
What To Know: BigBear.ai on Tuesday announced its participation in Project Convergence &#8211; Capstone 5 (PC-C5),&nbsp;a combined joint and multinational experiment allowing partners and allies&nbsp;to integrate resources and technologies in support of defense transformation efforts.
The PC-C5 experiment allowed multinational forces to test Next Generation Command Control (NGC2) systems. BigBear.ai said its Virtual Anticipation Network (VANE) platform helped forces gain situational awareness and identify emerging threats in the tests. 
&#8220;BigBear.ai is proud that VANE continues to demonstrate operational value in real-world exercises and experiments like PC-C5, involving forces from multiple nations,&#8221; said Ryan Legge, president of national security at BigBear.ai. 
&#8220;These environments validate the critical role AI plays in supporting faster, more accurate decision-making for warfighters.&#8221;
HC Wainwright &amp; Co. analyst Scott Buck maintained BigBear.ai with a Buy rating on Tuesday and raised the price target from&nbsp;$6&nbsp;to&nbsp;$9, citing strong business momentum. 
BigBear.ai stock is up approximately 52% year-to-date. Buck noted that the momentum in shares is being driven by <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46172406/bigbear-ai-bbai-stock-is-up-20-whats-going-on">new customers and contracts</a> combined with strong secular trends in AI defense and security. The analyst said the company&#8217;s products are resonating across key growth verticals and highlighted the company&#8217;s backlog of $384.9 million as of the first quarter. 
The HC Wainwright &amp; Co. analyst also noted that the company&#8217;s balance sheet provides opportunities to pursue M&amp;A that could drive revenue growth and create a faster path to profitability. 
&#8220;This positive momentum gives us greater confidence in our 2025 and 2026 revenue expectations and warrants an expansion in our valuation multiple to 12.0x from 10.0x,&#8221; Buck said in a note to clients. 
BBAI Price Action: <a href="http://Benzinga.com/quote/BBAI">BigBear.ai shares</a> were initially trading up but reversed 1.94% to $6.66 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46194043/apple-stock-analysis-july-sp500-seasonality">Apple Stock Had A Nightmare Year — But It May Be Nearing A Turning Point</a></li>
</ul>
Photo: PJ McDonnell/Shutterstock.com

BBAI

What's Going On With BigBear.AI Stock Tuesday?

JMP Securities analyst Trevor Walsh maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Market Outperform and raises the price target from $310 to $355.

JMP Securities Maintains Market Outperform on Zscaler, Raises Price Target to $355

<a href="We're Taking Time, For As Long As U.s. Economy Solid Prudent Thing Is To Wait">We're Taking Time, For As Long As U.s. Economy Solid Prudent Thing Is To Wait</a>

Macro Notification

Politics

Economics

General

Fed Chair Powell Says U.S. Economy In Pretty Good Position; If We Ignore Tariffs, Inflation Behaving As Expected And Hoped; We Expect Higher Readings Over Summer; We Went On Hold When We Saw Size Of The Tariffs; We're Taking Time, For As Long As U.S. Economy Solid Prudent Thing Is To Wait

Wells Fargo analyst Joseph O'Dea maintains Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) with a Equal-Weight and raises the price target from $225 to $240.

Wells Fargo Maintains Equal-Weight on Honeywell Intl, Raises Price Target to $240

Paramount Global (NASDAQ: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4445410-1%26h%3D372079487%26u%3Dhttps%253A%252F%252Fwww.prnewswire.com%252Fnews-releases%252Fparamount-global-declares-quarterly-cash-dividend-302473563.html%2523financial-modal%26a%3DPARA&amp;esheet=54284278&amp;newsitemid=20250701658403&amp;lan=en-US&amp;anchor=PARA&amp;index=1&amp;md5=e05ffb2ff7c900cee2447204fb197ab4">PARA</a>, PARAA) and Mediacom today announced the renewal of their comprehensive distribution agreements to continue providing Paramount's leading portfolio of broadcast, entertainment, news, and sports brands across Mediacom markets.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250701658403/en/">https://www.businesswire.com/news/home/20250701658403/en/</a>
The multi-year agreements extend Mediacom's carriage of Paramount's premier networks, including CBS, BET, Comedy Central, MTV, Nickelodeon and Paramount Network. As part of the renewal, Mediacom can now make the Paramount+ Premium plan available to qualifying Mediacom customers.

Contracts

PARA

PARAA

Paramount Global and Mediacom Renew Multi-Year Distribution Deal, Adding Paramount+ Premium Access For Qualifying Customers

Baird analyst Daniel Moore reinstates Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Underperform and announces $25 price target.

Initiation

WERN

Baird Reinstates Underperform on Werner Enterprises, Announces $25 Price Target

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares are trading higher Tuesday after the company initiated its pre-packed restructuring process, filing for <a href="https://www.benzinga.com/pressreleases/25/06/b46183949/wolfspeed-takes-next-step-to-implement-restructuring-support-agreement-and-proactively-strengthen-">Chapter 11 bankruptcy</a>.
What Happened: Wolfspeed said it has taken the next step to implement its previously announced Restructuring Support Agreement with key lenders.
Wolfspeed expects to emerge from the process with 70% less debt, representing a reduction of approximately $4.6 billion. The company said the restructuring will help it be better positioned to focus on long-term growth and accelerate its path to profitability.
In order to implement the prepackaged plan, Wolfspeed voluntarily filed for Chapter 11 bankruptcy. The company expects to emerge from the process by the end of the third quarter of 2025.
&#8220;We are continuing to move forward with our accelerated restructuring process to strengthen our capital structure and fuel our next phase of growth,&#8221; said Robert Feurle, CEO of Wolfspeed.
&#8220;With a stronger financial foundation, Wolfspeed will be better positioned to move faster on our strategic priorities and maintain our position as a global leader in the silicon carbide market. The strong support of our lenders is a testament to their belief in our business and our ability to capitalize on the opportunities ahead, driven by our exceptional, purpose-built, fully automated 200mm manufacturing footprint.&#8221;
Wolfspeed said it&#8217;s continuing to operate normally while it goes through the bankruptcy process, delivering silicon carbide materials and devices to customers. The company filed multiple customary motions with the court to support operations throughout the process. Wolfspeed expects to receive approval for the requests &#8220;shortly.&#8221;
WOLF Price Action: <a href="http://benzinga.com/quote/WOLF">Wolfspeed shares</a> were up 83.0% at approximately 72 cents at the time of publication Tuesday, according to Benzinga Pro. Wolfspeed shares are down more than 90% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46189380/nvidias-chinese-rivals-look-to-cash-in-on-us-tech-ban-moore-threads-metax-plot-1-65-billion-ipo">Nvidia&#8217;s Chinese Rivals Look To Cash In On US Tech Ban: Moore Threads, MetaX Plot $1.65 Billion IPO</a></li>
</ul>
Photo: T. Schneider/Shutterstock.com

WOLF

Why Wolfspeed Stock Is Ripping Higher Today

Small Cap Consumer Research analyst Eric Beder maintains Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) with a Buy and raises the price target from $58 to $65.

Small Cap Consumer Research Maintains Buy on Build-A-Bear Workshop, Raises Price Target to $65

Baird analyst Daniel Moore reinstates Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Neutral and announces $231 price target.

Baird Reinstates Neutral on Union Pacific, Announces $231 Price Target

Offerings

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Increases Offering Price Of Ordinary Shares Under Sales Agreement Dated Mar. 14 From $1.9M To $7.1M

Galaxy Gaming, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLXZ#OTC">GLXZ</a>), the world's leading independent developer and distributor of casino table games and technology, and Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>), a leading games, IP and toy entertainment company, today announced they have entered into a multi-year licensing agreement through which Galaxy Gaming will bring Hasbro's iconic games to casino table game pits.
Under the terms of the agreement, Galaxy Gaming will develop and distribute casino table games based on Hasbro's world-famous titles, including MONOPOLY, YAHTZEE, and BATTLESHIP. This partnership marries Galaxy Gaming's expertise in creating thrilling casino experiences with the nostalgic joy and distinctive excitement of Hasbro's beloved global brands. Casino patrons will soon enjoy the familiar rush of MONOPOLY, the suspense of rolling dice in YAHTZEE, and the explosive thrill of BATTLESHIP all reimagined for the table games pit.

GLXZ

Galaxy Gaming And Hasbro Sign Multi-Year Licensing Deal To Bring MONOPOLY, YAHTZEE, And BATTLESHIP To Casino Table Games

Small Cap Consumer Research analyst Eric Beder reiterates a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy and maintains $30 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $30 Price Target

Scandinavian Airlines (SAS) has entered into an agreement to acquire 45 Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>, B3: EMBR3))) E195-E2 aircraft, with purchase rights for an additional 10 aircraft — the largest SAS jet order direct from a manufacturer since 1996. This milestone agreement supports SAS' long-term fleet renewal strategy, which is focused on increasing efficiency, reducing emissions, and unlocking future growth opportunities from its global hub in Copenhagen as well as across its Scandinavian and international network.
The first aircraft deliveries from Embraer are scheduled to begin in late 2027, with further deliveries extending over approximately four years. Excluding purchase rights, the value for the order is approximately US$4 billion.

Embraer-Empresa Brasileira De Aeronautica

SAS Orders 45 Embraer E195-E2 Jets With Option For 10 More In ~$4B Deal, First Deliveries Set For Late 2027

Baird analyst Daniel Moore reinstates Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Outperform and announces $28 price target.

SNDR

Baird Reinstates Outperform on Schneider National, Announces $28 Price Target

Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">treatment-resistant depression </a>(TRD).
The study achieved its primary endpoint as well as all key secondary endpoints.
In June, the companies announced their plan to combine in an all-share transaction, subject to the pre-agreed <a href="https://www.benzinga.com/pressreleases/25/06/g45716633/atai-life-sciences-and-beckley-psytech-to-combine-creating-a-global-leader-in-psychedelic-mental-h">Phase 2b success criteria</a> for BPL-003 (mebufotenin benzoate).
The transaction is expected to close in the second half of 2025. 
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/25/05/45601096/ex-govt-foe-joins-trump-rfk-jr-s-hhs-to-lead-psychedelics-policy-what-it-means-for-investors" rel="noreferrer noopener">Ex-Gov&#8217;t Foe Joins Trump, RFK Jr.&#8217;s HHS To Lead Psychedelics Policy: What It Means For Investors</a>
<h2 class="wp-block-heading">Key Efficacy Findings:</h2>
At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg <a href="https://www.benzinga.com/pressreleases/25/07/g46189490/atai-life-sciences-and-beckley-psytech-announce-positive-topline-results-from-the-phase-2b-study-o" target="_blank" rel="noreferrer noopener">comparator group (p = 0.0038)</a>.
For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p = 0.0025 for change vs. the 0.3 mg control). The 8mg and 12mg of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with these effects generally maintained through Week 8.
The 8 mg and 12 mg doses of BPL-003 demonstrated equivalent efficacy, suggesting the 8 mg dose may be sufficient to achieve therapeutic benefit from a single dose.
The difference in MADRS scores between the 8 mg and 12 mg doses versus the 0.3 mg dose were statistically significant in both active arms from as early as Day 2, with mean MADRS reductions from baseline of 8.8 points in the 8 mg group and 8.9 points in the 12 mg group observed at that timepoint, compared to a reduction from baseline of 3.9 points in the 0.3 mg group.
These mean reductions from baseline increased to 11.1 points in the 8 mg group and 10.8 points in the 12 mg group at Day 8.
A durable effect was also observed for both higher doses, with the 8 mg group showing a mean reduction of 10.8 points from baseline at Day 57 and the 12 mg group showing a mean reduction of 10.2 points from baseline compared with the 0.3 mg group (5.2 point reduction).
<h2 class="wp-block-heading">Key Safety Findings:</h2>
Safety and efficacy results from this study support the selection of the 8 mg dose of BPL-003 for advancement into Phase 3 clinical studies.
More than 99% of treatment-emergent adverse events (TEAEs) were mild or moderate; there were no drug-related serious adverse events (SAEs).
Dose-related increases in administration site discomfort, nausea, headache, blood pressure, and anxiety suggest that the 8mg dose was better tolerated than the 12mg dose.
No participants in the 8 mg or 12 mg arms had any instance of treatment-emergent suicidal intent or behaviour, indicating no suicide-related safety signal observed to date.
Follow-up in the study&#8217;s eight-week open-label extension (OLE) stage is ongoing.
The OLE study evaluates the safety and efficacy of a second 12 mg BPL-003 administered to patients eight weeks after dosing in the core study. Data from the OLE study is expected in the third quarter of 2025 and will provide additional insights into the safety and tolerability of repeat dosing, as well as the durability of BPL-003&#8217;s antidepressant effect.
Concurrently, on Tuesday, Atai Life Sciences announced the private placement of 18.3 million shares with a nominal value of €0.10 (approximately $0.11) and pre-funded warrants to purchase 4.6 million shares, with approximately <a href="https://www.benzinga.com/pressreleases/25/07/g46189588/atai-life-sciences-announces-50-million-private-placement-financing" target="_blank" rel="noreferrer noopener">$50 million in gross proceeds</a>.
Price Action: ATAI stock was up 28.3% at $2.81 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/07/46193030/johnson-johnsons-drug-discount-plan-gets-thrown-out-in-court" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Drug Discount Plan Gets Thrown Out In Court</a></li>
</ul>
Photo: Shutterstock

Cannabis

Psychedelics

Health Care

Trading Ideas

ATAI

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

RBC Capital analyst Mike Dahl maintains GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) with a Sector Perform and raises the price target from $95.2 to $110.

RBC Capital Maintains Sector Perform on GMS, Raises Price Target to $110

WIIM

DDC Enterprise shares are trading higher after the company announced the closing of its $528 million capital financing round with Anson Funds to advance its Bitcoin treasury strategy.

Comments

GRAYSCALE ETHRM CLSSIC TR by Grayscale Ethereum Classic Trust (ETC)

GRAYSCALE ETHRM CLSSIC TR by Grayscale Ethereum Classic Trust (ETC) (ETCG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL